Clinical Trial Recruitment in Orphan Diseases - Patient Numbers in Ovarian Cancer Trials Exceed Other Orphan Diseases in Oncology - GBI Research Reports

Clinical Trial Recruitment in Orphan Diseases - Patient Numbers in Ovarian Cancer Trials Exceed Other Orphan Diseases in Oncology

Clinical Trial Recruitment in Orphan Diseases - Patient Numbers in Ovarian Cancer Trials Exceed Other Orphan Diseases in Oncology - GBI Research Reports
Clinical Trial Recruitment in Orphan Diseases - Patient Numbers in Ovarian Cancer Trials Exceed Other Orphan Diseases in Oncology
Published Nov 07, 2011
123 pages — Published Nov 07, 2011
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

GBI Research, the leading business intelligence provider, has released its latest research, Clinical Trial Recruitment in Orphan Diseases - Patient Numbers in Ovarian Cancer Trials Exceed Other Orphan Diseases in Oncology. It gives a robust idea about the patient recruitment status by geography, by Sponsor Company and by year for all the major orphan diseases in CNS and oncology. The report also compares the clinical trials and patient recruitment in orphan diseases with other diseases in CNS and oncology. Furthermore, the report provides profiles of prevalence forecast data up to 2017 for all the major indications. The major indications covered in the report are Huntingtons disease, Amyotrophic Lateral Sclerosis (ALS), ovarian disease, pancreatic disease, Hodgkins lymphoma, multiple myeloma and Acute Myeloid Leukemia (AML). It is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Researchs team of industry experts.

An orphan disease is not common and its occurrence is said to be rare. These diseases have a low rate of prevalence in the existing population and a physician rarely gets to see patients with these conditions. Most of the orphan diseases are often genetic and hence they persist throughout a persons life. It is estimated that 80% of orphan diseases have genetic origins. The remaining occurs due to allergies, degenerative causes, proliferative causes and as a result of infection. The symptoms for these diseases are not immediate and it occurs late for most of the conditions. The definition of orphan diseases varies with geography and is primarily dependent upon the prevalence of a disease.

In the US, orphan diseases are those that affect fewer than 6.6 per 10,000 (Orphan drug Act 1983). The US National Organization for Rate Disorders (NORD) has more than 1,200 diseases in their list while National Institute of Health (NIH)s office for rare diseases published a list of more than 6,000 disease disorders ranging from Aagenaes syndrome to Zuskas Disease. In Europe, orphan diseases are those that have a prevalence of less than 5 per 10,000 of the population. According to European Organization for Rare Diseases (EURORDIS), there are about 6,000 to 8,000 orphan diseases that exist in Europe. In Japan, orphan diseases are those that have a prevalence of less then 4 per 10,000 (Orphan Drug Act 1993).

The regulatory bodies play a crucial role in defining the orphan diseases as well as providing incentives to manufacturers who are involved in development of orphan drugs. Before the approval of orphan drugs, every molecule is designated as an orphan drug and will enter clinical trials. It is approved as an orphan drug only after the molecule clears the various phases in a clinical trial.

Clinical trials are one of the most critical parts of the drug development process. The various aspects involved in clinical trials such as implementation of technology, efficient supply chain management, proper site selection, patient recruitment, database management and others are important. Clinical trial recruitment is a time consuming process therefore good strategies need to be followed by pharmaceutical companies for adequate patient recruitment.

Scope

- Insight on Clinical Trials conducted for major indications of cardiology such as Huntingtons disease, ALS, ovarian cancer, pancreatic cancer, Hodgkins lymphoma, multiple myeloma and AML from 2000 to 2010.
- The status of patient recruitment by geography, Sponsor Company, year and stage of development.
- The comparison of clinical trials and patient recruitment in orphan diseases with other diseases in CNS and oncology
- Analysis on the average number of patients recruited per trial for major indications per year.
- Anal

  
Source:
Document ID
GBIHC157MR
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents310
  List of Tables54
  List of Figures94
Clinical Trials in Orphan Diseases: Introduction131
  Disease Overview131
    The US131
    Europe131
    Japan131
  GBI Research Report Guidance131
Clinical Trials and Patient Recruitment for Orphan Diseases in Central Nervous System(CNS)1432
  Huntington s disease141
    Introduction141
    Number of Clinical Trials for Huntington s disease151
      Number of Clinical Trials by Phase151
      Number of Clinical Trials by Major Sponsors161
      Number of Clinical Trials by Geography171
      Number of Clinical Trials by Year181
    Prevalence Population for Huntington s disease (2010-2017)191
      The US191
      Europe201
      Japan211
    Patient Recruitment for Huntington s Disease221
      Number of Patients Recruited by Phase of Clinical Trials221
      Number of Patients Recruited by Major Sponsors231
      Number of Patients Recruited by Geography241
      Number of Patients Recruited per Year251
    Average Number of Patients Recruited Per Trial261
      Average Number of Patients Recruited per Trial by Stage of Development261
      Average Number of Patients Recruited per Trial per Year271
  Amyotrophic Lateral Sclerosis (ALS)281
    Introduction281
    Number of Clinical Trials for Amyotrophic Lateral Sclerosis291
      Number of Clinical Trials by Phase291
      Number of Clinical Trials by Sponsor301
      Number of Clinical Trials by Geography311
      Number of Clinical Trials by Year321
    Prevalence Population for ALS (2010-2017)331
      The US331
      Europe341
      Japan351
    Patient Recruitment for Amyotrophic Lateral Sclerosis361
      Number of Patients Recruited By Phase of Clinical Trial361
      Number of Patients Recruited By Sponsor371
      Number of Patients Recruited By Geography381
      Number of Patients Recruited per Year391
    Average Number of Patients Recruited Per Trial401
      Average Number of Patients Recruited per Trial by Stage of Development401
      Average Number of Patients Recruited per Trial per Year411
  Comparison of Clinical Trials and Patient Recruitment of Orphan Diseases with Other CNS Diseases421
    Number of Clinical Trials421
    Number of Patients Recruited431
    Average Number of Patients Recruited per Phase441
    Average Number of Patients Recruited per Year451
Clinical Trials and Patient Recruitment for Orphan Diseases in Oncology4674
  Ovarian Cancer461
    Introduction461
    Number of Clinical Trials for Ovarian Cancer471
      Number of Clinical Trials by Phase471
      Number of Clinical Trials by Major Sponsor481
      Number of Clinical Trials by Geography491
      Number of Clinical Trials by Year501
    Prevalence Population for Ovarian Cancer (2010-2017)511
      The US511
      Europe521
      Japan531
    Patient Recruitment for Ovarian Cancer541
      Number of Patients Recruited By Phase of Clinical Trial541
      Number of Patients Recruited by Major Sponsors551
      Number of Patients Recruited by Geography561
      Number of Patients Recruited per Year571
    Average Number of Patients Recruited Per Trial581
      Average Number of Patients Recruited per Trial by Stage of Development581
      Average Number of Patients Recruited per Trial per Year591
  Pancreatic Cancer601
    Introduction601
    Number of Clinical Trials for Pancreatic Cancer611
      Number of Clinical Trials by Phase611
      Number of Clinical Trials by Major Sponsors621
      Number of Clinical Trials by Geography631
      Number of Clinical Trials by Year641
    Prevalence Population for Pancreatic Cancer (2010-2017)651
      The US651
      Europe661
      Japan671
    Patient Recruitment for Pancreatic cancer681
      Number of Patients Recruited By Phase of Clinical Trial681
      Number of Patients Recruited by Major Sponsors691
      Number of Patients Recruited By Geography701
      Number of Patients Recruited Per Year711
    Average Number of Patients Recruited Per Trial721
      Average Number of Patients Recruited per Trial by Stage of Development721
      Average Number of Patients Recruited per Trial per Year731
  Multiple Myeloma741
    Introduction741
    Number of Clinical Trials for Multiple Myeloma751
      Number of Clinical Trials by Phase751
      Number of Clinical Trials by Sponsor761
      Number of Clinical Trials by Geography771
      Number of Clinical Trials by Year781
    Prevalence Population for Multiple Myeloma (2010-2017)791
      The US791
      Europe801
      Japan811
    Patient Recruitment for Multiple Myeloma821
      Number of Patients Recruited By Phase of Clinical Trial821
      Number of Patients Recruited By Major Sponsors831
      Number of Patients Recruited By Geography841
      Number of Patients Recruited Per Year851
    Average Number of Patients Recruited Per Trial861
      Average Number of Patients Recruited per Trial by Stage of Development861
      Average Number of Patients Recruited per Trial per Year871
  Hodgkin s Lymphoma881
    Introduction881
    Number of Clinical Trials for Hodgkin s Lymphoma881
      Number of Clinical Trials by Phase882
      Number of Clinical Trials by Sponsor901
      Number of Clinical Trials by Geography911
      Number of Clinical Trials by Year921
    Prevalence Population for Hodgkin s Lymphoma (2010-2017)931
      The US931
      Europe941
      Japan951
    Patient Recruitment for Hodgkin s Lymphoma961
      Number of Patients Recruited By Phase of Clinical Trial961
      Number of Patients Recruited By Major Sponsors971
      Number of Patients Recruited By Geography981
      Number of Patients Recruited Per Year991
    Average Number of Patients Recruited Per Trial1001
      Average Number of Patients Recruited per Trial by Stage of Development1001
      Average Number of Patients Recruited per Trial per Year1011
  Acute Myelocytic Leukemia (AML)1021
    Introduction1021
    Number of Clinical Trials for Acute Myelocytic Leukemia1031
      Number of Clinical Trials by Phase1031
      Number of Clinical Trials by Sponsor1041
      Number of Clinical Trials by Geography1051
      Number of Clinical Trials by Year1061
    Prevalence Population for Acute Myelocytic Leukemia (2010-2017)1071
      The US1071
      Europe1081
      Japan1091
    Patient Recruitment for Multiple Myeloma1101
      Number of Patients Recruited By Phase of Clinical Trial1101
      Number of Patients Recruited By Major Sponsors1111
      Number of Patients Recruited By Geography1121
      Number of Patients Recruited Per Year1131
    Average Number of Patients Recruited Per Trial1141
      Average Number of Patients Recruited per Trial by Stage of Development1141
      Average Number of Patients Recruited per Trial per Year1151
  Comparison of Clinical Trials and Patient Recruitment of Orphan Diseases with Other Oncology Diseases1161
    Number of Clinical Trials1161
    Number of Patients Recruited1171
    Average Number of Patients Recruited per Phase1181
    Average Number of Patients Recruited per Year1191
Clinical Trial Recruitment in Orphan Diseases-Appendix1204
  Market Definitions1201
  Abbreviations1201
  Research Methodology1203
    Coverage1201
    Secondary Research1211
    Primary Research1211
    Expert Panel Validation1211
    Section-wise methodology1211
      Clinical Trials Overview1221
      Number of Clinical Trials1221
      Patient Recruitment Status1221
      Prevalence of Disease in the US, Europe and Japan (2010-2017)1221
  Contact Us1231
  Disclaimer1231
  Sources1231

Table Of Contents

GBI Research Reports—GBI Research covers worldwide markets and issues, supplies actionable data and forecasts and is driven by industry leaders' insights. GBI Research provides a broad spectrum of reports across the healthcare and energy industries and its online offering is easy to navigate - a comprehensive resource for business information needs.

About the Author


Cite this Report

  
MLA:
GBI Research Reports. "Clinical Trial Recruitment in Orphan Diseases - Patient Numbers in Ovarian Cancer Trials Exceed Other Orphan Diseases in Oncology" Nov 07, 2011. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Clinical-Trial-Recruitment-in-Orphan-Diseases-Patient-Numbers-in-Ovarian-Cancer-Trials-Exceed-Other-Orphan-Diseases-in-Oncology-2115-296>
  
APA:
GBI Research Reports. (2011). Clinical Trial Recruitment in Orphan Diseases - Patient Numbers in Ovarian Cancer Trials Exceed Other Orphan Diseases in Oncology Nov 07, 2011. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Clinical-Trial-Recruitment-in-Orphan-Diseases-Patient-Numbers-in-Ovarian-Cancer-Trials-Exceed-Other-Orphan-Diseases-in-Oncology-2115-296>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.